New eczema drug candidate passes first safety check in small study
NCT ID NCT06193434
First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 38 times
Summary
This early-stage study tested the safety and tolerability of a new drug called IBI356 in 99 participants, including healthy volunteers and people with atopic dermatitis (a type of eczema). The main goal was to check for side effects and how the drug moves through the body. No claims of effectiveness or cure were made.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Skin Disease Hospital
Shanghai, Shanghai Municipality, 200443, China
Conditions
Explore the condition pages connected to this study.